Business Description
I-MAB
ISIN : US44975P1030
Share Class Description:
IMAB: ADRDescription
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.07 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -76.1 | |||||
| 3-Year Book Growth Rate | -37.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.3 | |||||
| 9-Day RSI | 30.72 | |||||
| 14-Day RSI | 40.96 | |||||
| 6-1 Month Momentum % | 8.98 | |||||
| 12-1 Month Momentum % | -38.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.67 | |||||
| Quick Ratio | 5.67 | |||||
| Cash Ratio | 5.55 | |||||
| Days Sales Outstanding | 7.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4 | |||||
| Shareholder Yield % | -1.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4422.33 | |||||
| Net Margin % | -5304.17 | |||||
| FCF Margin % | -2073.6 | |||||
| ROE % | -61.51 | |||||
| ROA % | -42.68 | |||||
| ROIC % | -269.14 | |||||
| ROC (Joel Greenblatt) % | -1406.27 | |||||
| ROCE % | -52.01 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 38.37 | |||||
| PB Ratio | 0.59 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| EV-to-EBIT | 0.81 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.81 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | -43.02 | |||||
| EV-to-Forward-Revenue | 0.23 | |||||
| EV-to-FCF | 2.09 | |||||
| Price-to-Net-Current-Asset-Value | 0.7 | |||||
| Price-to-Net-Cash | 0.73 | |||||
| Earnings Yield (Greenblatt) % | 123.46 | |||||
| FCF Yield % | -56.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
I-MAB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.864 | ||
| EPS (TTM) ($) | -2.464 | ||
| Beta | 1.21 | ||
| Volatility % | 54.38 | ||
| 14-Day RSI | 40.96 | ||
| 14-Day ATR ($) | 0.060195 | ||
| 20-Day SMA ($) | 1.7995 | ||
| 12-1 Month Momentum % | -38.31 | ||
| 52-Week Range ($) | 1.16 - 3.45 | ||
| Shares Outstanding (Mil) | 80.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
I-MAB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
I-MAB Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
I-MAB Frequently Asked Questions
What is I-MAB(IMAB)'s stock price today?
The current price of IMAB is $1.76. The 52 week high of IMAB is $3.45 and 52 week low is $1.16.
When is next earnings date of I-MAB(IMAB)?
The next earnings date of I-MAB(IMAB) is 2024-08-16 Est..
Does I-MAB(IMAB) pay dividends? If so, how much?
I-MAB(IMAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers